share_log

BRIEF-Puma Biotechnology And Pierre Fabre Amend Nerlynx License Agreement

路透社 ·  Feb 26, 2021 07:40
Feb 25 (Reuters) - Puma Biotechnology Inc :
   * PUMA BIOTECHNOLOGY AND PIERRE FABRE AMEND NERLYNX® LICENSE AGREEMENT TO INCLUDE GREATER CHINA
   * PUMA BIOTECHNOLOGY INC - CO, CANBRIDGE PHARMACEUTICALS TERMINATE LICENSE AGREEMENT IN GREATER CHINA
   * PUMA BIOTECHNOLOGY INC - UNDER TERMS, CO WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION
   * PUMA BIOTECHNOLOGY - UNDER TERMS, CO WILL RECEIVE AN ADDITIONAL REGULATORY, SALES-BASED MILESTONE PAYMENTS THAT COULD ADD UP TO AN ADDITIONAL $240 MILLION
   * PUMA BIOTECHNOLOGY INC - IN ADDITION, PUMA WILL RECEIVE SIGNIFICANT DOUBLE-DIGIT TIERED ROYALTIES ON SALES OF NERLYNX IN GREATER CHINA

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment